Login / Signup

Second-Line Gemcitabine Plus Nab-Paclitaxel for Patients with Unresectable Advanced Pancreatic Cancer after First-Line FOLFIRINOX Failure.

Naoki MitaTakuji IwashitaShinya UemuraKensaku YoshidaYuhei IwasaNobuhiro AndoKeisuke IwataMitsuru OkunoTsuyoshi MukaiMasahito Shimizu
Published in: Journal of clinical medicine (2019)
Second-line GnP after FX failure for patients with APC could be more effective than GEM alone. Further comparison studies are warranted.
Keyphrases
  • locally advanced
  • rectal cancer
  • squamous cell carcinoma
  • radiation therapy
  • liver metastases
  • epidermal growth factor receptor